Kamau Therapeutics Emerges from Stealth With Clinical-Stage Novel Gene Correction Technology Targeting Life-Threatening Genetic Diseases

SAN FRANCISCO–(BUSINESS WIRE)– #ASH23–Kamau Therapeutics (“Kamau” or “the Company”), a clinical-stage gene correction company, announced today its emergence from stealth, following a strategic transaction with Graphite Bio (“Graphite”). Under the terms of the agreement, Kamau received an option to acquire all genome editing assets, including a platform technology that integrates…
Click here to view original post

Advertisement — Advertise with Biotech Networks